Optimizing Patient Outcomes in High-Risk HR+, HER2- Early-Stage Breast Cancer - Episode 3

5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide an in-depth analysis of the randomized phase III monarchE trial, which focused on Abemaciclib in high-risk early-stage HR+, HER2- breast cancer, offering insights into recurrence rates, progression-free survival, and distant disease-free survival outcomes for patients.

EP. 1: HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification
EP. 2: NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer
Now Viewing
EP. 3: 5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer
EP. 4: The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer
EP. 5: AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes
EP. 6: Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape

This OncLive Insights video series was supported by an independent sponsorship from Eli Lilly. Eli Lilly had no input into the content or development of this OncLive Insights video series. Content was independently developed and published by OncLive.